Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최명근 | - |
dc.date.accessioned | 2024-05-10T16:30:42Z | - |
dc.date.available | 2024-05-10T16:30:42Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.other | OAK-35283 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/268077 | - |
dc.description.abstract | Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, their real-world effectiveness remains unknown. Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in ES-SCLC in actual clinical settings. Materials and Methods In this multicenter prospective cohort study, patients with ES-SCLC receiving or scheduled to receive atezolizumab in combination with etoposide and carboplatin were enrolled between June 2021 and August 2022. The primary outcomes were progression-free survival (PFS) and the 1-year overall survival (OS) rate. Results A total of 100 patients with ES-SCLC were enrolled from seven centers. Median age was 69 years, and 6% had an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2. The median PFS was 6.0 months, the 1-year OS rate was 62.2%, and the median OS was 13.5 months. An ECOG PS of 2-3 and progressive disease as the best response were poor prognostic factors for PFS, while an ECOG PS of 2-3 and brain metastasis were associated with poor prognosis for OS. In addition, consolidative thoracic radiotherapy was found to be an independent favorable prognostic factor for OS (hazard ratio, 0.336; p=0.021). Grade ≥ 3 treatment-related adverse events were observed in 7% of patients, with treatment-related deaths occurring in 2% of patients. Conclusion We provided evidence of the favorable real-world effectiveness and safety of atezolizumab plus chemotherapy in ES-SCLC patients, including in the elderly and those with poor ECOG PS. Additional consolidative thoracic radiotherapy may also benefit ES-SCLC patients. © 2024 Korean Cancer Association. All rights reserved. | - |
dc.language | English | - |
dc.publisher | Korean Cancer Association | - |
dc.subject | Atezolizumab | - |
dc.subject | Real-world | - |
dc.subject | Small cell lung carcinoma | - |
dc.title | The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study | - |
dc.type | Article | - |
dc.relation.issue | 2 | - |
dc.relation.volume | 56 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.index | KCI | - |
dc.relation.startpage | 422 | - |
dc.relation.lastpage | 429 | - |
dc.relation.journaltitle | Cancer Research and Treatment | - |
dc.identifier.doi | 10.4143/crt.2023.913 | - |
dc.identifier.scopusid | 2-s2.0-85190353375 | - |
dc.author.google | Choi | - |
dc.author.google | Myeong Geun | - |
dc.author.google | Kim | - |
dc.author.google | Yeon Joo | - |
dc.author.google | Lee | - |
dc.author.google | Jae Cheol | - |
dc.author.google | Ji | - |
dc.author.google | Wonjun | - |
dc.author.google | Oh | - |
dc.author.google | In-Jae | - |
dc.author.google | Sung Yong | - |
dc.author.google | Yoon | - |
dc.author.google | Seong Hoon | - |
dc.author.google | Shin Yup | - |
dc.author.google | Jeong Eun | - |
dc.author.google | Eun Young | - |
dc.author.google | Chang-Min | - |
dc.contributor.scopusid | 최명근(57210423283) | - |
dc.date.modifydate | 20240510142425 | - |